Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
DVAX$$$$$ $20 TARGET PRICE WOOHOOOOOOOOOOOOOOO
Hit the Golden Cross....looks like a strong trend higher.
We had our pullback to mid-bollie band...now we are on the next leg.
l make sure Dynavax is listed on my Virus stock opportunity discussion board.
I don't see it posted there.
Home > Boards > Free Zone > Health and Sciences > Coronavirus COVID-19 Medical Science Plays
VSYM video? Major huge volume today.
* * $DVAX Video Chart 06-01-2020 * *
Link to Video - click here to watch the technical chart video
Price jumped from $4+ to $7 after that article.
Me too. Followed cause it was mentioned in an article 4-5 days ago.
Thought my son would be interested.
Too hot for me.
Outstanding Shares
92,184,031
05/01/2020
Dr. Stanley Plotkin "The Father Of Vaccines", INO Scientific Advisory Board.
Emeritus Professor, Wistar Institute and University of Pennsylvania; Principal, Vaxconsult
Stanley Plotkin developed the rubella vaccine now used worldwide and has worked extensively on the development and application of other vaccines, including polio, rabies, varicella, rotavirus, and cytomegalovirus. He is Emeritus Professor, Wistar Institute and the University of Pennsylvania, and is a principal of Vaxconsult.
Over the course of his career he has served as senior assistant surgeon with the Epidemic Intelligence Service of the U.S. Public Health Service; Chairman of the Infectious Diseases Committee and the AIDS Task Force of the American Academy of Pediatrics; Chairman of the Microbiology and Infectious Diseases Research Committee of the National Institutes of Health; director of the Division of Infectious Diseases at Children’s Hospital of Philadelphia; Associate Chairman of the Department of Pediatrics, University of Pennsylvania; Medical and Scientific Director of Aventis Pasteur; and Executive Advisor to Sanofi Pasteur. Over 600 of his articles have been published, and he has edited several books, including Vaccines, now the standard textbook in the field.
Dr. Plotkin’s numerous professional awards include:
The medal of the Fondation Mérieux (2007)
The Fleming (Bristol) Award of the Infectious Diseases Society of America (2004)
The Sabin Foundation Medal (2002)
The French Legion Medal of Honor (1998)
The Clinical Virology Award, Pan American Group for Rapid Viral Diagnosis (1995)
The Distinguished Physician Award, Pediatric Infectious Disease Society (1993)
The Bruce Medal of the American College of Physicians (1987)
Dr. Plotkin earned his M.D. at the State University of New York, Downstate College of Medicine, and holds honorary degrees from the University of Pennsylvania and the University of Rouen (France). He serves on the Board of Directors of Dynavax and is Chairman of the Scientific Advisory Board of Mymetics, while also serving as an International Society for Vaccines advisor.
https://www.inovio.com/about-inovio/scientific-advisory-board/
Chairman of Scientific Advisory Board of an unknown penny stock company?
* * $DVAX Video Chart 05-29-2020 * *
Link to Video - click here to watch the technical chart video
Yes, I think once retail soak in the news there will be plenty of interest next week.
That price still below Upper Bollinger Limit, 6.31.
Yes I got in late at 6.02 but hey Monday morning should be interesting
Were we supposed to hear about progress regarding the virus after markets closed?
* * $DVAX Video Chart 05-19-2020 * *
Link to Video - click here to watch the technical chart video
Dynavax
Market value: $448.0 million
TipRanks consensus price target: $16.00 (229% upside potential)
TipRanks consensus rating: Strong Buy
Dynavax (DVAX, $4.86), which takes advantage of the body's own immune responses to create effective vaccines, is among the health and pharmaceutical companies battling the COVID-19 coronavirus. However, while it has grabbed headlines for its collaborations on developing a COVID-19 vaccine, DVAX already has an approved vaccine for hepatitis B.
For the first quarter of 2020, sales of Dynavax's Heplisav-B came in at $10.5 million. While this missed the $11.3 million consensus estimate, it surpassed H.C. Wainwright analyst Edward White's $10 million call. Sales did slip by 0.5% on a sequential basis, which was chalked up to the pandemic.
But White pointed out that in late March, Dynavax said the European Medicines Agency accepted the company's application for Heplisav-B, which has a targeted approval in the first quarter of 2021. So White remains firm on this year's goals and sees big things down the road. "We maintain our 2021 revenue estimate of $74.4 million," he writes. "We estimate sales will rise to $236 million in 2028."
Heplisav-B also is being studied in other indications. Dynavax recently published interim data from the HBV-4 trial enrolling patients undergoing hemodialysis showing that it was both effective and well-tolerated. White is looking forward to the release of the complete results.
"Full data from the trial are still expected in 2H20 as this study has not been impacted by the pandemic; people on dialysis need to remain on dialysis despite COVID-19," he writes. "Hemodialysis represents about 16% of the hepatitis B market, and we believe increased share and overall growth of this market could drive sales of Heplisav-B."
White has a Buy rating and a $12 price target on shares, conveying high confidence - and the potential for shares to jump 147% over the next year. A small group of analysts covering the stock have dished out three Buy ratings versus no Holds or Sells over the past quarter. You can learn more about the analyst community's views on DVAX via TipRanks' consensus breakdown.
Whoa! What happened after hours?
* * $DVAX Video Chart 05-06-2020 * *
Link to Video - click here to watch the technical chart video
DVAX is up +16% something is brewing behind the scene.. Guessing they will have a good earnings tomorrow..
I hear you I've added a couple times when it dipped..
Dynavax Technologies, Valneva Team Up for Covid-19 Vaccine Program
6:44 am ET April 23, 2020 (Dow Jones) Print
By Chris Wack
Valneva SE and Dynavax Technologies Corp. said they are collaborating to initiate a vaccine program for Covid-19.
Valneva is providing its platform for IXIARO, its commercial vaccine product indicated for active immunization for the prevention of Japanese encephalitis. This platform operates on a highly purified Vero-cell based, inactivated, whole virus strategy for vaccine development.
Dynavax is providing technical expertise and its proprietary toll-like receptor 9 agonist adjuvant, CpG 1018, the adjuvant used in Hepatitis B Vaccine Recombinant, an adult hepatitis B vaccine approved by the U.S. Food and Drug Administration. Dynavax developed CpG 1018 to provide an increased vaccine immune response. CpG 1018 provides a well-developed technology and a significant safety database, potentially accelerating the development and large-scale manufacturing of a COVID-19 vaccine.
Valneva will use its Biosafety Level 3 laboratory capabilities to rapidly leverage its large scale, Vero-based, viral Good Manufacturing Practice manufacturing facility in Livingston, Scotland.
$DVAX The World Health Organization warned that there is no evidence antibody tests can show if a person who was previously affected by the novel coronavirus is immune to reinfection.
Actually sold this last Wed. Watching for another entry
Good buying I wish I have more ammo..
When they announced the deal with Albertsons people are now realizing time to get on the DVAX train.. Yesterday and today's trading days are the indicators.. Glad I've added at $4.49 and $5.41
Better be a damn good earnings CALL
I think they will beat. 10.3 million average estimate. We'll see.
Will see if there's meat in their earnings tomorrow...
Think about the possibility of a sell on the news and lock in some profit. Then a retrace and buy again.
DVAX has been creeping up Joe..Could it be the sells are started to pick up? Hope we see double in sells this upcoming earnings..
Good for you. I bought back in at $4.83. The charts are finally looking good.
Recently bought 500 more shares @ $4.49 I am glad I did so this is going to take off sooner or later..
GO DVAX!
3 Penny Stocks Making New Highs In September
$MRNS $DVAX $ABEO
https://www.transparenttraders.me/2019/09/3-penny-stocks-making-new-highs-in.html
* * $DVAX Video Chart 09-03-2019 * *
Link to Video - click here to watch the technical chart video
* * $DVAX Video Chart 08-09-2019 * *
Link to Video - click here to watch the technical chart video
* * $DVAX Video Chart 06-17-2019 * *
Link to Video - click here to watch the technical chart video
Followers
|
108
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2538
|
Created
|
10/09/06
|
Type
|
Free
|
Moderators |
We are developing cutting-edge vaccines by utilizing our innovative adjuvant technology and our expertise of Toll-like Receptor (TLR) biology to modulate the immune system.
HEPLISAV-B®
[HEPATITIS B VACCINE (RECOMBINANT) ADJUVANTED]
During the uncertainty caused by the COVID-19 pandemic, Dynavax has acted quickly to focus on four key areas
– these include safeguarding the health and safety of our employees and customers; continuing effective operations
to ensure patient access to HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted]; maintaining our financial strength and stability;
and supporting efforts to develop a COVID-19 vaccine.
Shs Outstand | 85.48M |
Shs Float | 84.14M |
Short Float | 18.11% |
Debt/Eq | 15.22 |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |